Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:clinicalTrials.govIdentifier |
NCT04039503
|
| gptkbp:comparator |
gptkb:insulin
|
| gptkbp:conditionStudied |
gptkb:type_2_diabetes
|
| gptkbp:enrollment |
475
|
| gptkbp:fullName |
A Study of Tirzepatide (LY3298176) Versus Insulin Glargine in Participants With Type 2 Diabetes Not Adequately Controlled on Insulin Glargine With or Without Metformin
|
| https://www.w3.org/2000/01/rdf-schema#label |
SURPASS-5
|
| gptkbp:intervention |
gptkb:tirzepatide
|
| gptkbp:location |
multinational
|
| gptkbp:primaryCompletionDate |
2021
|
| gptkbp:publicationYear |
2022
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
change in HbA1c
change in body weight tirzepatide superior to insulin glargine for HbA1c and weight reduction |
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
2019
|
| gptkbp:studyType |
double-blind
randomized parallel assignment |
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|